Dr Ashleys Executes Strategic Merger with Impact BioMedical
Deal News | Jun 23, 2025 | Globenewswire
Dr. Ashleys Limited and Impact BioMedical Inc. have announced a merger agreement that marks a crucial advancement in the pharmaceutical sector, particularly in the development and commercialization of innovative patents. With the strategic merger completed through a reverse merger agreement, the newly formed company, known as the PubCo, will trade under the name Dr. Ashleys Limited on the NYSE American. The merger aims to leverage Dr. Ashleys' expansive global footprint and financial strength, along with Impact BioMedical's extensive intellectual property portfolio, to accelerate the development of transformative pharmaceutical solutions. Both companies focus on combating a range of pervasive health issues, including infectious diseases and noncommunicable diseases, through their research and development endeavors. The process is awaiting regulatory approvals and shareholder agreement, supported by the legal and financial advisory services of multiple firms, as it positions the combined entity for substantial growth in healthcare innovation.
Sectors
- Pharmaceuticals
- Biotechnology
- Financial Services
Geography
- United States – Impact BioMedical is based in Texas and the PubCo will be listed on the NYSE American.
- Hong Kong – Dr. Ashleys is a global pharmaceutical company based in Hong Kong, indicating its geographical significance.
- Cayman Islands – Dr Ashleys Bio Labs Limited is a Cayman Islands exempted company, which is part of the merger transaction.
Industry
- Pharmaceuticals – The article revolves around companies involved in the development and manufacturing of pharmaceuticals and biopharmaceutical innovations.
- Biotechnology – Impact BioMedical is involved in biopharmaceuticals, focusing on innovative health solutions, making the biotechnology sector relevant.
- Financial Services – The involvement of multiple financial advisors and legal counsel in facilitating the merger transaction underscores the role of financial services.
Financials
- Not specified – The article does not provide specific financial details, such as the enterprise value or financial terms of the merger.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Dr Ashleys Limited | Purchaser | Company | A Hong Kong-based global pharmaceutical company focusing on innovative drug development. |
| Impact BioMedical Inc. | Target | Company | A Texas-based biopharmaceutical developer with a significant patent portfolio. |
| BMI Capital LLC | M&A and Capital Markets Advisor | Company | Providing M&A and capital markets advisory services to Dr Ashleys. |
| Robinson & Cole LLP | U.S. Legal Counsel | Company | Offering legal services to Dr Ashleys on U.S. regulatory matters. |
| Harney Westwood & Riegels | Cayman Islands Legal Counsel | Company | Serving as legal counsel for Dr Ashleys regarding Cayman Islands legal matters. |
| Sichenzia Ross Ference Carmel LLP | U.S. Legal Counsel | Company | Providing U.S. legal counsel to Impact BioMedical. |
| Revere Securities LLC | M&A Advisor | Company | Advising Impact BioMedical on the merger transaction. |
| Capital Formation Marketing, LLC | Public Relations | Company | Serving as investor relations and public relations advisor for the transaction. |